BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5921 related articles for article (PubMed ID: 3707060)

  • 1. Antitumor metallocenes: new developments and toxicologic features.
    Köpf-Maier P; Köpf H
    Anticancer Res; 1986; 6(2):227-33. PubMed ID: 3707060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
    Köpf-Maier P
    Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma.
    Köpf-Maier P; Köpf H
    Arzneimittelforschung; 1987 May; 37(5):532-4. PubMed ID: 3619974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor inhibition by titanocene complexes: activity against sarcoma 180.
    Köpf-Maier P; Preiss F; Marx T; Klapötke T; Köpf H
    Anticancer Res; 1986; 6(1):33-7. PubMed ID: 3954328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of an ionic titanocene tetrachloroferrate derivative against some solid experimental tumors.
    Köpf-Maier P; Klapötke T
    Arzneimittelforschung; 1989 Apr; 39(4):488-90. PubMed ID: 2751735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
    Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
    Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor inhibition by ferricenium complexes. Activity against some solid experimental tumors.
    Köpf-Maier P; Klapötke T
    Arzneimittelforschung; 1989 Mar; 39(3):369-71. PubMed ID: 2757661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
    Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action.
    Porter CW; Bernacki RJ; Miller J; Bergeron RJ
    Cancer Res; 1993 Feb; 53(3):581-6. PubMed ID: 8425191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of titanocene dihalides against a human colon carcinoma heterotransplanted to athymic mice.
    Köpf-Maier P; Moormann A; Köpf H
    Eur J Cancer Clin Oncol; 1985 Jul; 21(7):853-7. PubMed ID: 4043173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumour metallocenes: structure-activity studies and interactions with biomolecules.
    Harding MM; Mokdsi G
    Curr Med Chem; 2000 Dec; 7(12):1289-303. PubMed ID: 11032972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Titanocene dichloride--the first metallocene with cancerostatic activity.
    Köpf H; Köpf-Maier P
    Angew Chem Int Ed Engl; 1979 Jun; 18(6):477-8. PubMed ID: 111586
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of phthalmustine, a new anticancer compound. II. Tumor inhibitory effect in murine Ehrlich ascites carcinoma and sarcoma-180.
    Bhattacharya S; Ghosh M; Sadhu U; Dutta S; Sanyal U
    Neoplasma; 1996; 43(3):209-13. PubMed ID: 8841510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.
    Moebus VJ; Stein R; Kieback DG; Runnebaum IB; Sass G; Kreienberg R
    Anticancer Res; 1997; 17(2A):815-21. PubMed ID: 9137413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of dichlorobis(1-phenylbutane-1,3-dionato)titanium (IV) and budotitane. Two representatives of the new class of antitumor-active bis-beta-diketonato metal complexes.
    Keppler BK; Schmähl D
    Arzneimittelforschung; 1986 Dec; 36(12):1822-8. PubMed ID: 3566844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ionic titanocene complexes: a new type of antitumor agent.
    Köpf-Maier P; Neuse E; Klapötke T; Köpf H
    Cancer Chemother Pharmacol; 1989; 24(1):23-7. PubMed ID: 2720888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
    Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
    Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2 (X=F, Cl, Br, I, NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects.
    Köpf-Maier P; Hesse B; Voigtländer R; Köpf H
    J Cancer Res Clin Oncol; 1980; 97(1):31-9. PubMed ID: 7400205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of toxicity by titanocene dichloride in mice: hematologic parameters.
    Köpf-Maier P; Gerlach S
    Anticancer Res; 1986; 6(2):235-40. PubMed ID: 3707061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 297.